Qube Research & Technologies (QRT)
ARTV

Qube Research & Technologies (QRT)’s Artiva Biotherapeutics ARTV Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,552
Closed -$73.3K – 4173
2025
Q3 		$73.3K Sell
25,552
-13,140
-34% -$35.2K ﹤0.01% 3116
2025
Q2 		$58.4K Buy
+38,692
New +$81.3K ﹤0.01% 3125

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ARTV Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 25,552 shares — an estimated $73.3K sold.

Qube Research & Technologies (QRT) first reported a position in ARTV in Q2 2025 and held it in 2 quarters. The position peaked at $73.3K in Q3 2025. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • Qube Research & Technologies (QRT) reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 25,552 Artiva Biotherapeutics shares in Q4 2025, an estimated $73.3K.
  • Qube Research & Technologies (QRT) first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • Qube Research & Technologies (QRT)'s Artiva Biotherapeutics position peaked at $73.3K in Q3 2025.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.